DGAP-News: Biotest AG: Annual general meeting approves dividend
(firmenpresse) - DGAP-News: Biotest AG / Key word(s): AGM/EGM
Biotest AG: Annual general meeting approves dividend
10.05.2012 / 15:30
---------------------------------------------------------------------
PRESS RELEASE
Biotest AG: Annual general meeting approves dividend
- Distribution of EUR 0.44 per ordinary share and EUR 0.50 per preference
share
- Dr. Alessandro Banchi elected as new Supervisory Board Chairman
Dreieich / Frankfurt a. M., 10 May 2012. At the annual general meeting
(AGM) held on 10 May 2012 in Frankfurt am Main shareholders of Biotest AG
approved payment of a dividend. With 81,49 percent of the share capital
represented at the meeting, a payment of EUR 0.44 per ordinary share and
EUR 0.50 per preference share met with wide endorsement. This equates to a
dividend increase of 15.8% relative to last year for ordinary shares and
13.6% for preference shares. The overall distribution will amount to EUR
5.5 million.
The AGM also took a decision on the new composition of the Supervisory
Board whose term of office expired at the conclusion of the meeting. At his
own request, the previous Supervisory Board Chairman Dr. Thorlef Spickschen
does not stand again for the Board. He is succeeded by the new Supervisory
Board member Dr. Alessandro Banchi, who was elected along with existing
members Dr. Cathrin Schleussner and Thomas Jakob by a large majority.
Another new member, Dr. Christoph Schröder, was also widely endorsed in
place of Professor Dr. Marbod Muff who is stepping down. Jürgen Heilmann
and Kerstin Birkhahn will again join the Board as employee representatives
for a further five years.
Professor Dr. Gregor Schulz, Chairman of the Management Board of the
Biotest Group, thanked the retiring Chairman of the Supervisory Board, Dr.
Thorlef Spickschen, warmly for his commitment to the company's development.
'Since taking office in 2005, Dr. Spickschen has been a valuable supporter
of Biotest with his extensive experience of the pharmaceutical industry.
Under his chairmanship important decisions for the future of Biotest have
been taken e.g. the acquisition of Nabi Biologics in 2007. Both the
Management and Supervisory Boards would therefore like to thank him
sincerely for his extraordinary commitment,' said Professor Dr. Schulz.
Professor Dr. Marbod Muff, who did not stand again for the Supervisory
Board, was also given a warm send-off: 'Professor Dr. Muff has supported
the development of Biotest since his appointment in 2008. His wide
expertise of finance and accountancy issues in particular has been highly
valued but also his input for the business development have been greatly
appreciated,' Professor Dr. Schulz concluded.
The annual general meeting attended by around 89 shareholders and guests
also formally discharged the members of the Management and Supervisory
Boards for financial year 2011 and endorsed all of the other agenda items
by a large majority.
The full text of the address given by Professor Gregor Schulz at the AGM is
available at: http://www.biotest.de/ww/de/pub/investor_relations/
hauptversammlung.cfm.
Disclaimer
This document contains forward-looking statements on overall economic
development as well as on the business, earnings, financial and assets
position of Biotest AG and its subsidiaries. These statements are based on
current plans, estimates, forecasts and expectations of the company and are
thus subject to risks and elements of uncertainty that could result in
significant deviation of actual developments from expected developments.
The forward-looking statements are only valid at the time of publication.
Biotest does not intend to update the forward-looking statements and
assumes no obligation to do so.
About Biotest
Biotest is a provider of pharmaceutical and biotherapeutic drugs. With a
value added chain that extends from pre-clinical and clinical development
to worldwide sales, Biotest has specialised primarily in the areas of
application of clinical immunology, haematology and intensive medicine. In
its Plasma Protein segment, Biotest develops and markets immunoglobulins,
coagulation factors and albumins based on human blood plasma. These are
used for diseases of the immune and haematopoietic systems. In the
Biotherapeutic segment, Biotest researches into the clinical development of
monoclonal antibodies, including in the indications of rheumatoid arthritis
and cancer of plasma cells. Biotest has more than 1.600 employees
worldwide. The preference shares of Biotest AG are listed in the SDAX on
the Frankfurt stock exchange.
Biotest AG, Landsteinerstr. 5, 63303 Dreieich, www.biotest.de
Dr. Monika Buttkereit
tel.: +49 (0) 6103 801-4406,
e-mail: investor_relations(at)biotest.de
fax: +49 (0) 6103 801-347
Securities' ID No., ISIN ordinary shares: 522720, DE0005227201
Securities' ID No., ISIN preference shares: 522723, DE0005227235
Listing: Prime Standard
Open Market: Berlin-Bremen, Düsseldorf, Frankfurt, Hamburg, Hannover,
München, Stuttgart
End of Corporate News
---------------------------------------------------------------------
10.05.2012 Dissemination of a Corporate News, transmitted by DGAP - a
company of EquityStory AG.
The issuer is solely responsible for the content of this announcement.
DGAP's Distribution Services include Regulatory Announcements,
Financial/Corporate News and Press Releases.
Media archive at www.dgap-medientreff.de and www.dgap.de
---------------------------------------------------------------------
Language: English
Company: Biotest AG
Landsteinerstraße 5
63303 Dreieich
Germany
Phone: 0 61 03 - 8 01-0
Fax: 0 61 03 - 8 01-150
E-mail: investor_relations(at)biotest.de
Internet: http://www.biotest.de
ISIN: DE0005227235, DE0005227201
WKN: 522723, 522720
Indices: SDAX
Listed: Regulierter Markt in Frankfurt (Prime Standard);
Freiverkehr in Berlin, Düsseldorf, Hamburg, Stuttgart
End of News DGAP News-Service
---------------------------------------------------------------------
169228 10.05.2012
Themen in dieser Pressemitteilung:
Unternehmensinformation / Kurzprofil:
Datum: 10.05.2012 - 15:30 Uhr
Sprache: Deutsch
News-ID 145103
Anzahl Zeichen: 6915
contact information:
Kategorie:
Business News
Diese Pressemitteilung wurde bisher 333 mal aufgerufen.
Die Pressemitteilung mit dem Titel:
"DGAP-News: Biotest AG: Annual general meeting approves dividend"
steht unter der journalistisch-redaktionellen Verantwortung von
Biotest AG (Nachricht senden)
Beachten Sie bitte die weiteren Informationen zum Haftungsauschluß (gemäß TMG - TeleMedianGesetz) und dem Datenschutz (gemäß der DSGVO).
